These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21307076)

  • 1. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes.
    Fourlanos S; Perry C; Gellert SA; Martinuzzi E; Mallone R; Butler J; Colman PG; Harrison LC
    Diabetes; 2011 Apr; 60(4):1237-45. PubMed ID: 21307076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.
    Harrison LC; Honeyman MC; Steele CE; Stone NL; Sarugeri E; Bonifacio E; Couper JJ; Colman PG
    Diabetes Care; 2004 Oct; 27(10):2348-55. PubMed ID: 15451899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
    Walter M; Philotheou A; Bonnici F; Ziegler AG; Jimenez R;
    Diabetes Care; 2009 Nov; 32(11):2036-40. PubMed ID: 19690081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults.
    Kupila A; Sipilä J; Keskinen P; Simell T; Knip M; Pulkki K; Simell O
    Diabetes Metab Res Rev; 2003; 19(5):415-20. PubMed ID: 12951650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.
    Aspord C; Thivolet C
    Clin Exp Immunol; 2002 Nov; 130(2):204-11. PubMed ID: 12390307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
    Bonifacio E; Ziegler AG; Klingensmith G; Schober E; Bingley PJ; Rottenkolber M; Theil A; Eugster A; Puff R; Peplow C; Buettner F; Lange K; Hasford J; Achenbach P;
    JAMA; 2015 Apr; 313(15):1541-9. PubMed ID: 25898052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin.
    Monetini L; Cavallo MG; Sarugeri E; Sentinelli F; Stefanini L; Bosi E; Thorpe R; Pozzilli P;
    Diabetologia; 2004 Oct; 47(10):1795-802. PubMed ID: 15502927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes.
    Yuki Y; Hara-Yakoyama C; Guadiz AA; Udaka S; Kiyono H; Chatterjee S
    Biotechnol Bioeng; 2005 Dec; 92(7):803-9. PubMed ID: 16142801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.
    Wang XH; Xu F; Cheng M; Wang X; Zhang DM; Zhao LH; Cai HL; Huang HY; Chen T; Zhang XL; Wang XQ; Cheng XB; Su JB; Lu Y
    Endocr J; 2020 Nov; 67(11):1107-1117. PubMed ID: 32684527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
    Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
    Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes.
    Every AL; Kramer DR; Mannering SI; Lew AM; Harrison LC
    J Immunol; 2006 Apr; 176(8):4608-15. PubMed ID: 16585551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-based vaccination and prevention of type 1 diabetes.
    Harrison LC; Wentworth JM; Zhang Y; Bandala-Sanchez E; Böhmer RM; Neale AM; Stone NL; Naselli G; Bosco JJ; Auyeung P; Rashidi M; Augstein P; Morahan G
    Curr Diab Rep; 2013 Oct; 13(5):616-23. PubMed ID: 23888323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.
    Akimoto H; Fukuda-Kawaguchi E; Duramad O; Ishii Y; Tanabe K
    J Diabetes Res; 2019; 2019():9430473. PubMed ID: 31781669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
    Näntö-Salonen K; Kupila A; Simell S; Siljander H; Salonsaari T; Hekkala A; Korhonen S; Erkkola R; Sipilä JI; Haavisto L; Siltala M; Tuominen J; Hakalax J; Hyöty H; Ilonen J; Veijola R; Simell T; Knip M; Simell O
    Lancet; 2008 Nov; 372(9651):1746-55. PubMed ID: 18814906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure.
    Zavala AV; Fabiano de Bruno LE; Cardoso AI; Mota AH; Capucchio M; Poskus E; Fainboim L; Basabe JC
    Diabetologia; 1992 Dec; 35(12):1159-64. PubMed ID: 1478368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
    Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
    Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
    Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered B:9-23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes.
    Kobayashi M; Abiru N; Arakawa T; Fukushima K; Zhou H; Kawasaki E; Yamasaki H; Liu E; Miao D; Wong FS; Eisenbarth GS; Eguchi K
    J Immunol; 2007 Aug; 179(4):2082-8. PubMed ID: 17675466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Co-administration of intranasally delivered insulin and proinsulin C-peptide to rats with the types 1 and 2 diabetes mellitus restores their metabolic parameters.].
    Derkach KV; Bondareva VM; Shpakov AO
    Adv Gerontol; 2017; 30(6):851-858. PubMed ID: 29608829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.